RARX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
RARX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ra Pharmaceuticals's Average Total Inventories for the quarter that ended in Dec. 2019 was $0.00 Mil. Ra Pharmaceuticals's Revenue for the three months ended in Dec. 2019 was $0.00 Mil.
Ra Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2019 stayed the same from Sep. 2019 (0.00) to Sep. 2019 (0.00)
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Inventory Turnover measures how fast the company turns over its inventory within a year.
The historical data trend for Ra Pharmaceuticals's Inventory-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ra Pharmaceuticals Annual Data | |||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | |||||||||
Inventory-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
Ra Pharmaceuticals Quarterly Data | |||||||||||||||||||
Dec14 | Sep15 | Dec15 | Mar16 | Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | |
Inventory-to-Revenue | Get a 7-Day Free Trial | - | - | - | - | - |
For the Biotechnology subindustry, Ra Pharmaceuticals's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Ra Pharmaceuticals's Inventory-to-Revenue distribution charts can be found below:
* The bar in red indicates where Ra Pharmaceuticals's Inventory-to-Revenue falls into.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Ra Pharmaceuticals's Inventory-to-Revenue for the fiscal year that ended in Dec. 2019 is calculated as
Inventory-to-Revenue (A: Dec. 2019 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (A: Dec. 2018 ) | + | Total Inventories (A: Dec. 2019 )) | / | count ) | / | Revenue (A: Dec. 2019 ) |
= | ( (0 | + | 0) | / | 1 ) | / | 3 |
= | 0 | / | 3 | ||||
= | 0.00 |
Ra Pharmaceuticals's Inventory-to-Revenue for the quarter that ended in Dec. 2019 is calculated as
Inventory-to-Revenue (Q: Dec. 2019 ) | |||||||
= | Average Total Inventories | / | Revenue | ||||
= | ( (Total Inventories (Q: Sep. 2019 ) | + | Total Inventories (Q: Dec. 2019 )) | / | count ) | / | Revenue (Q: Dec. 2019 ) |
= | ( (0 | + | 0) | / | 1 ) | / | 0 |
= | 0 | / | 0 | ||||
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ra Pharmaceuticals (NAS:RARX) Inventory-to-Revenue Explanation
An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:
1. investment in inventory is growing more rapidly than revenueLikewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:
1. investment in inventory is shrinking in relation to revenueMore Related Terms:
1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Ra Pharmaceuticals's Days Inventory for the three months ended in Dec. 2019 is calculated as:
Days Inventory | = | Average Total Inventories (Q: Dec. 2019 ) | / | Cost of Goods Sold (Q: Dec. 2019 ) | * | Days in Period |
= | 0 | / | 0 | * | 365 / 4 | |
= |
2. Inventory Turnover measures how fast the company turns over its inventory within a year.
Ra Pharmaceuticals's Inventory Turnover for the quarter that ended in Dec. 2019 is calculated as
Inventory Turnover | = | Cost of Goods Sold (Q: Dec. 2019 ) | / | Average Total Inventories (Q: Dec. 2019 ) |
= | 0 | / | 0 | |
= |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Thank you for viewing the detailed overview of Ra Pharmaceuticals's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Peter Kolchinsky | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Edward T Mathers | director | C/O MEDIMMUNE, INC., ONE MEDIMMUNE WAY, GAITHERSBURG MD 20878 |
Timothy R Pearson | director | C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451 |
Aoife Brennan | director | 200 SIDNEY STREET, SUITE 320, C/O SYNLOGIC, INC., CAMBRIDGE MA 02139 |
Douglas A Treco | director, officer: President and CEO | 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140 |
Nea Partners 13, Limited Partnership | 10 percent owner | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
Nea 13 Gp, Ltd | 10 percent owner | 1119 ST. PAUL STREET, BALTIMORE MD 21202 |
New Enterprise Associates 13 Lp | 10 percent owner | 1119 ST PAUL STREET, BALTIMORE MD 21202 |
Rajeev M. Shah | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Alexander Cumbo | director | 215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142 |
Robert Heft | director | 87 CAMBRIDGEPARK DRIVE, C/O RA PHARMACEUTICALS, INC., CAMBRIDGE MA 02140 |
Patrick J Kerins | 10 percent owner | |
Ra Capital Management, L.p. | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
Ra Capital Healthcare Fund Lp | director, 10 percent owner | 200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116 |
David Charles Lubner | officer: Executive VP and CFO | C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472 |
From GuruFocus
By Marketwired Marketwired • 10-16-2019
By Marketwired Marketwired • 10-15-2019
By Marketwired Marketwired • 11-26-2019
By PRNewswire PRNewswire • 10-10-2019
By Marketwired Marketwired • 11-01-2019
By Marketwired Marketwired • 10-10-2019
By Marketwired Marketwired • 08-15-2018
By James Li James Li • 10-10-2019
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.